Phase 1b/2, Open Label, study of Alcalabrutinib alone or in combination with Rituximab in subjects with Indolent B-Cell, Non-Hodgkins Lymphoma (MZL)

Type of Cancer
Lymphoma

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase 1b/2, Open Label, study of Alcalabrutinib alone or in combination with Rituximab in subjects with Indolent B-Cell, Non-Hodgkins Lymphoma (MZL)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.